Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.

MLA

Etminan, M., et al. “Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease: A Meta-Analysis of Randomised Controlled Trials.” Drug Safety, vol. 24, no. 11, Aug. 2001, pp. 863–68. EBSCOhost, https://doi.org/10.2165/00002018-200124110-00007.

APA

Etminan, M., Samii, A., Takkouche, B., & Rochon, P. A. (2001). Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trials. Drug Safety, 24(11), 863–868. https://doi.org/10.2165/00002018-200124110-00007

Chicago

Etminan, M., A. Samii, B. Takkouche, and P.A. Rochon. 2001. “Increased Risk of Somnolence with the New Dopamine Agonists in Patients with Parkinson’s Disease: A Meta-Analysis of Randomised Controlled Trials.” Drug Safety 24 (11): 863–68. doi:10.2165/00002018-200124110-00007.